

Chiara Dalla Man

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4745170/publications.pdf>

Version: 2024-02-01

171
papers

12,720
citations

30551

56
h-index

29333

108
g-index

174
all docs

174
docs citations

174
times ranked

9954
citing authors

#	ARTICLE	IF	CITATIONS
1	A New Oral Model to Assess Postprandial Lactate Production Rate. IEEE Transactions on Biomedical Engineering, 2022, 69, 1533-1540.	2.5	2
2	The Effect of Diabetes-Associated Variation in <i>TCF7L2</i> on Postprandial Glucose Metabolism When Glucagon and Insulin Concentrations Are Matched. Metabolic Syndrome and Related Disorders, 2022, , .	0.5	2
3	A software interface for in silico testing of type 2 diabetes treatments. Computer Methods and Programs in Biomedicine, 2022, 223, 106973.	2.6	1
4	The relationship between insulin and glucagon concentrations in non-diabetic humans. Physiological Reports, 2022, 10, .	0.7	1
5	Assessment of individual and standardized glucagon kinetics in healthy humans. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E71-E77.	1.8	8
6	Limitations of the fasting proinsulin to insulin ratio as a measure of β -cell health in people with and without impaired glucose tolerance. European Journal of Clinical Investigation, 2021, 51, e13469.	1.7	8
7	Insulin Pulse Characteristics and Insulin Action in Non-diabetic Humans. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1702-1709.	1.8	5
8	Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia. Frontiers in Endocrinology, 2021, 12, 611253.	1.5	6
9	Modeling Between-Subject Variability in Subcutaneous Absorption of a Fast-Acting Insulin Analogue by a Nonlinear Mixed Effects Approach. Metabolites, 2021, 11, 235.	1.3	6
10	Adipose tissue macrophage populations and inflammation are associated with systemic inflammation and insulin resistance in obesity. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E105-E121.	1.8	55
11	Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials. Journal of Diabetes Science and Technology, 2021, , 193229682110152.	1.3	7
12	Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide. Diabetes, Obesity and Metabolism, 2021, 23, 1795-1805.	2.2	26
13	Exercise Effect on Insulin-Dependent and Insulin-Independent Glucose Utilization in Healthy and Type 1 Diabetes Individuals. A Modeling Study.. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E122-E129.	1.8	12
14	Determinants of hepatic insulin clearance – Results from a Mendelian Randomization study. Metabolism: Clinical and Experimental, 2021, 119, 154776.	1.5	2
15	Modeling Intraperitoneal Insulin Absorption in Patients with Type 1 Diabetes. Metabolites, 2021, 11, 600.	1.3	3
16	Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in non-diabetic subjects. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E728-E736.	1.8	4
17	Response to Comment on “Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials”. Journal of Diabetes Science and Technology, 2021, , 193229682110600.	1.3	0
18	Modeling Between-Subject Variability in Subcutaneous Absorption of a Long-Acting Insulin Glargine 100 U/mL by a Nonlinear Mixed Effects Approach. , 2021, 2021, 4226-4229.		0

#	ARTICLE	IF	CITATIONS
19	Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes. IEEE Transactions on Biomedical Engineering, 2020, 67, 624-631.	2.5	11
20	Inducing remission of Type 2 diabetes in the Caribbean: findings from a mixed methods feasibility study of a low-calorie liquid diet-based intervention in Barbados. Diabetic Medicine, 2020, 37, 1816-1824.	1.2	19
21	Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 640-647.	2.2	27
22	Visual food cues decrease blood glucose and gluco-regulatory hormones following an oral glucose tolerance test in normal-weight and obese men. Physiology and Behavior, 2020, 226, 113071.	1.0	5
23	Hyperglycemia But Not Hyperinsulinemia Is Favorable for Exercise in Type 1 Diabetes: A Pilot Study. Diabetes Care, 2020, 43, 2176-2182.	4.3	11
24	A Reduced Incretin Effect Mediated by the rs7903146 Variant in the TCF7L2 Gene Is an Early Marker of β -Cell Dysfunction in Obese Youth. Diabetes Care, 2020, 43, 2553-2563.	4.3	10
25	In Silico Cloning of Target Type 2 Diabetes Population for Treatments Development and Decision Support*. , 2020, 2020, 5111-5114.		2
26	Diabetes-associated genetic variation in TCF7L2 alters pulsatile insulin secretion in humans. JCI Insight, 2020, 5, .	2.3	14
27	The Padova Type 2 Diabetes Simulator from Triple-Tracer Single-Meal Studies: <i>In Silico</i> Trials Also Possible in Rare but Not-So-Rare Individuals. Diabetes Technology and Therapeutics, 2020, 22, 892-903.	2.4	16
28	<i>In Silico</i> Head-to-Head Comparison of Insulin Glargine 300%U/mL and Insulin Degludec 100%U/mL in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 553-561.	2.4	14
29	Fasting glucagon concentrations are associated with longitudinal decline of β -cell function in non-diabetic humans. Metabolism: Clinical and Experimental, 2020, 105, 154175.	1.5	14
30	Metabolic and Genetic Determinants of Glucose Shape After Oral Challenge in Obese Youths: A Longitudinal Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 534-542.	1.8	8
31	A novel natural tracer method to measure complex carbohydrate metabolism. American Journal of Physiology - Endocrinology and Metabolism, 2019, 317, E483-E493.	1.8	7
32	Letter to the Editor: "Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes". Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5106-5107.	1.8	0
33	Mechanisms of hyperinsulinaemia in apparently healthy non-obese young adults: role of insulin secretion, clearance and action and associations with plasma amino acids. Diabetologia, 2019, 62, 2310-2324.	2.9	17
34	Physiological models for artificial pancreas development. , 2019, , 123-152.		2
35	Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for <i>In Silico</i> Testing of MDI Therapies. IEEE Transactions on Biomedical Engineering, 2019, 66, 2889-2896.	2.5	14
36	Assessment of pulsatile insulin secretion derived from peripheral plasma C-peptide concentrations by nonparametric stochastic deconvolution. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E687-E694.	1.8	5

#	ARTICLE	IF	CITATIONS
37	Intranasal oxytocin fails to acutely improve glucose metabolism in obese men. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 424-428.	2.2	10
38	Contribution of endogenous glucagon-like peptide-1 to changes in glucose metabolism and islet function in people with type 2 diabetes four weeks after Roux-en-Y gastric bypass (RYGB). <i>Metabolism: Clinical and Experimental</i> , 2019, 93, 10-17.	1.5	16
39	Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance. <i>Journal of the Endocrine Society</i> , 2019, 3, 135-145.	0.1	2
40	Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis. <i>Molecular Psychiatry</i> , 2019, 24, 1513-1522.	4.1	32
41	Physiology-Based Run-to-Run Adaptation of Insulin to Carbohydrate Ratio Improves Type 1 Diabetes Therapy: Results from an In Silico Study. , 2019, , .		2
42	The UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 273-281.	1.3	169
43	Impaired Insulin Action Is Associated With Increased Glucagon Concentrations in Nondiabetic Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 314-319.	1.8	26
44	Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. <i>Diabetologia</i> , 2018, 61, 1142-1154.	2.9	30
45	Insulin Sensitivity Index-Based Optimization of Insulin to Carbohydrate Ratio: In Silico Study Shows Efficacious Protection Against Hypoglycemic Events Caused by Suboptimal Therapy. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 98-105.	2.4	15
46	Modeling Subcutaneous Absorption of Fast-Acting Insulin in Type 1 Diabetes. <i>IEEE Transactions on Biomedical Engineering</i> , 2018, 65, 2079-2086.	2.5	38
47	Performance of individually measured vs population-based $C_{peptide}$ kinetics to assess β -cell function in the presence and absence of acute insulin resistance. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 549-555.	2.2	13
48	Long-acting Insulin in Diabetes Therapy: In Silico Clinical Trials with the UVA/Padova Type 1 Diabetes Simulator. , 2018, 2018, 4905-4908.		2
49	Differential effects of the circadian system and circadian misalignment on insulin sensitivity and insulin secretion in humans. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2481-2485.	2.2	85
50	Three hours of intermittent hypoxia increases circulating glucose levels in healthy adults. <i>Physiological Reports</i> , 2017, 5, e13106.	0.7	42
51	Glucose metabolism during rotational shift-work in healthcare workers. <i>Diabetologia</i> , 2017, 60, 1483-1490.	2.9	76
52	The rs7903146 Variant in the <i>TCF7L2</i> Gene Increases the Risk of Prediabetes/Type 2 Diabetes in Obese Adolescents by Impairing β -Cell Function and Hepatic Insulin Sensitivity. <i>Diabetes Care</i> , 2017, 40, 1082-1089.	4.3	50
53	Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A1c and Hypoglycemia. <i>Diabetes Care</i> , 2017, 40, 1719-1726.	4.3	68
54	Liver triacylglycerol content and gestational diabetes: effects of moderate energy restriction. <i>Diabetologia</i> , 2017, 60, 306-313.	2.9	12

#	ARTICLE	IF	CITATIONS
55	Effect of Pramlintide on Postprandial Glucose Fluxes in Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1954-1962.	1.8	24
56	Long-Term Outcomes of Biliopancreatic Diversion on Glycemic Control, Insulin Sensitivity and Beta Cell Function. <i>Obesity Surgery</i> , 2016, 26, 2572-2580.	1.1	5
57	Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 904-914.	1.5	37
58	One-Day Bayesian Cloning of Type 1 Diabetes Subjects: Toward a Single-Day UVA/Padova Type 1 Diabetes Simulator. <i>IEEE Transactions on Biomedical Engineering</i> , 2016, 63, 2416-2424.	2.5	63
59	Mechanisms Underlying the Pathogenesis of Isolated Impaired Glucose Tolerance in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4816-4824.	1.8	10
60	Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β -Cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series. <i>Diabetes Care</i> , 2016, 39, 1602-1613.	4.3	47
61	Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 574-585.	2.4	29
62	Interstitial Fluid Glucose Is Not Just a Shifted-in-Time but a Distorted Mirror of Blood Glucose: Insight from an In Silico Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 505-511.	2.4	71
63	Model-Based Quantification of Glucagon-Like Peptide-1-Induced Potentiation of Insulin Secretion in Response to a Mixed Meal Challenge. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 39-46.	2.4	18
64	A Model for the Estimation of Hepatic Insulin Extraction After a Meal. <i>IEEE Transactions on Biomedical Engineering</i> , 2016, 63, 1925-1932.	2.5	19
65	<i>TCF7L2</i> Genotype and β -Cell Function in Humans Without Diabetes. <i>Diabetes</i> , 2016, 65, 371-380.	0.3	43
66	A common variant in the <i>MTNR1b</i> gene is associated with increased risk of impaired fasting glucose (IFG) in youth with obesity. <i>Obesity</i> , 2015, 23, 1022-9.	1.5	24
67	Exercise effects on postprandial glucose metabolism in type 1 diabetes: a triple-tracer approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E1106-E1115.	1.8	59
68	Modeling Plasma-to-Interstitial Glucose Kinetics from Multitracer Plasma and Microdialysis Data. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 825-831.	2.4	31
69	Incorporation of inhaled insulin into the FDA accepted University of Virginia/Padova Type 1 Diabetes Simulator. , 2015, 2015, 3250-3.		2
70	Circadian Variability of Insulin Sensitivity: Physiological Input for In Silico Artificial Pancreas. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 1-7.	2.4	84
71	Cholecalciferol Supplementation Does Not Influence β -Cell Function and Insulin Action in Obese Adolescents: A Prospective Double-Blind Randomized Trial. <i>Journal of Nutrition</i> , 2015, 145, 284-290.	1.3	36
72	Defects in Mitochondrial Efficiency and H ₂ O ₂ Emissions in Obese Women Are Restored to a Lean Phenotype With Aerobic Exercise Training. <i>Diabetes</i> , 2015, 64, 2104-2115.	0.3	89

#	ARTICLE	IF	CITATIONS
73	Epicardial and Pericardial Fat in Type 2 Diabetes: Favourable Effects of Biliopancreatic Diversion. <i>Obesity Surgery</i> , 2015, 25, 477-485.	1.1	10
74	An index of parameter reproducibility accounting for estimation uncertainty: theory and case study on \hat{I}^2 -cell responsiveness and insulin sensitivity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E971-E977.	1.8	2
75	Association Between Thyrotropin Levels and Insulin Sensitivity in Euthyroid Obese Adolescents. <i>Thyroid</i> , 2015, 25, 478-484.	2.4	19
76	Six and 12 Weeks of Caloric Restriction Increases \hat{I}^2 Cell Function and Lowers Fasting and Postprandial Glucose Concentrations in People with Type 2 Diabetes. <i>Journal of Nutrition</i> , 2015, 145, 2046-2051.	1.3	40
77	Nocturnal Glucose Metabolism in Type 1 Diabetes: A Study Comparing Single Versus Dual Tracer Approaches. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 587-595.	2.4	16
78	Glucagon sensitivity and clearance in type 1 diabetes: insights from in vivo and in silico experiments. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E474-E486.	1.8	15
79	Adjustment of Open-Loop Settings to Improve Closed-Loop Results in Type 1 Diabetes: A Multicenter Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3878-3886.	1.8	67
80	Hepatic insulin sensitivity in healthy and prediabetic subjects: from a dual- to a single-tracer oral minimal model. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E161-E167.	1.8	17
81	The effect of vagal nerve blockade using electrical impulses on glucose metabolism in nondiabetic subjects. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2014, 7, 305.	1.1	9
82	Multicenter Closed-Loop Insulin Delivery Study Points to Challenges for Keeping Blood Glucose in a Safe Range by a Control Algorithm in Adults and Adolescents with Type 1 Diabetes from Various Sites. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 613-622.	2.4	43
83	Glucose Modelling. , 2014, , 355-379.		0
84	The UVA/PADOVA Type 1 Diabetes Simulator. <i>Journal of Diabetes Science and Technology</i> , 2014, 8, 26-34.	1.3	587
85	The University of Virginia/Padova Type 1 Diabetes Simulator Matches the Glucose Traces of a Clinical Trial. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 428-434.	2.4	74
86	Co-occurrence of Risk Alleles in or Near Genes Modulating Insulin Secretion Predisposes Obese Youth to Prediabetes. <i>Diabetes Care</i> , 2014, 37, 475-482.	4.3	30
87	Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass. <i>Diabetes</i> , 2014, 63, 483-493.	0.3	123
88	Quantitative Estimation of Insulin Sensitivity in Type 1 Diabetic Subjects Wearing a Sensor-Augmented Insulin Pump. <i>Diabetes Care</i> , 2014, 37, 1216-1223.	4.3	43
89	Advancing Our Understanding of the Glucose System via Modeling: A Perspective. <i>IEEE Transactions on Biomedical Engineering</i> , 2014, 61, 1577-1592.	2.5	38
90	Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and \hat{I}^2 -cell function. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2014, 307, E494-E502.	1.8	26

#	ARTICLE	IF	CITATIONS
91	Ethnic Differences in Insulin Sensitivity, β -Cell Function, and Hepatic Extraction Between Japanese and Caucasians: A Minimal Model Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4273-4280.	1.8	83
92	The Oral Minimal Model Method. <i>Diabetes</i> , 2014, 63, 1203-1213.	0.3	169
93	Multicenter Closed-Loop/Hybrid Meal Bolus Insulin Delivery with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 623-632.	2.4	38
94	Postprandial improvement in insulin sensitivity after a single exercise session in adolescents with low aerobic fitness and physical activity. <i>Pediatric Diabetes</i> , 2013, 14, 129-137.	1.2	22
95	The Effect of a Bile Acid Sequestrant on Glucose Metabolism in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 1094-1101.	0.3	78
96	Diurnal Pattern of Insulin Action in Type 1 Diabetes. <i>Diabetes</i> , 2013, 62, 2223-2229.	0.3	94
97	Direct Effects of Exendin-(9,39) and GLP-1-(9,36)amide on Insulin Action, β -Cell Function, and Glucose Metabolism in Nondiabetic Subjects. <i>Diabetes</i> , 2013, 62, 2752-2756.	0.3	24
98	In Silico Design of Optimal Ratio for Co-Administration of Pramlintide and Insulin in Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 802-809.	2.4	19
99	Physical Activity Measured by Physical Activity Monitoring System Correlates with Glucose Trends Reconstructed from Continuous Glucose Monitoring. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 836-844.	2.4	23
100	Postprandial glucose fluxes and insulin sensitivity during exercise: A study in healthy individuals. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E557-E566.	1.8	36
101	β -Cell Function Improvements in Grade I/II Obese Subjects With Type 2 Diabetes 1 Month After Biliopancreatic Diversion: Results from modeling analyses of oral glucose tolerance tests and hyperglycemic clamp studies. <i>Diabetes Care</i> , 2013, 36, 4117-4124.	4.3	10
102	Day and Night Closed-Loop Control in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3882-3887.	4.3	95
103	Mechanism of Insulin Resistance in Normal Pregnancy. <i>Hormone and Metabolic Research</i> , 2013, 45, 567-571.	0.7	30
104	Modeling hepatic insulin sensitivity during a meal: validation against the euglycemic hyperinsulinemic clamp. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 304, E819-E825.	1.8	24
105	In Silico Optimization of Basal Insulin Infusion Rate during Exercise: Implication for Artificial Pancreas. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 1461-1469.	1.3	29
106	The Effect of Walking on Postprandial Glycemic Excursion in Patients With Type 1 Diabetes and Healthy People. <i>Diabetes Care</i> , 2012, 35, 2493-2499.	4.3	75
107	Defects in GLP-1 Response to an Oral Challenge Do Not Play a Significant Role in the Pathogenesis of Prediabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 589-598.	1.8	29
108	Diabetes-Associated Common Genetic Variation and Its Association With GLP-1 Concentrations and Response to Exogenous GLP-1. <i>Diabetes</i> , 2012, 61, 1082-1089.	0.3	36

#	ARTICLE	IF	CITATIONS
109	Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling. <i>Diabetes</i> , 2012, 61, 2269-2279.	0.3	142
110	Race Differences in the Association of Oxidative Stress With Insulin Sensitivity in African-American and European-American Women. <i>Obesity</i> , 2012, 20, 972-977.	1.5	18
111	Modular Closed-Loop Control of Diabetes. <i>IEEE Transactions on Biomedical Engineering</i> , 2012, 59, 2986-2999.	2.5	150
112	Fully Integrated Artificial Pancreas in Type 1 Diabetes. <i>Diabetes</i> , 2012, 61, 2230-2237.	0.3	343
113	Diurnal Pattern to Insulin Secretion and Insulin Action in Healthy Individuals. <i>Diabetes</i> , 2012, 61, 2691-2700.	0.3	195
114	A concerted decline in insulin secretion and action occurs across the spectrum of fasting and postchallenge glucose concentrations. <i>Clinical Endocrinology</i> , 2012, 76, 212-219.	1.2	37
115	MPC based Artificial Pancreas: Strategies for individualization and meal compensation. <i>Annual Reviews in Control</i> , 2012, 36, 118-128.	4.4	101
116	A Dynamic Risk Measure from Continuous Glucose Monitoring Data. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 843-852.	2.4	28
117	Assessment of Blood Glucose Predictors: The Prediction-Error Grid Analysis. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 787-796.	2.4	26
118	Multiscale Modeling of Insulin Secretion. <i>IEEE Transactions on Biomedical Engineering</i> , 2011, 58, 3020-3023.	2.5	18
119	Modeling and Control of Diabetes: Towards the Artificial Pancreas. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2011, 44, 7092-7101.	0.4	24
120	Age-Related Changes in Insulin Sensitivity and β -Cell Function Among European-American and African-American Women. <i>Obesity</i> , 2011, 19, 528-535.	1.5	31
121	The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose. <i>Clinical Endocrinology</i> , 2010, 73, 189-196.	1.2	54
122	Combination peroxisome proliferator-activated receptor β and δ agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content. <i>Diabetic Medicine</i> , 2010, 27, 150-156.	1.2	7
123	Downregulation of the Longevity-Associated Protein Sirtuin 1 in Insulin Resistance and Metabolic Syndrome: Potential Biochemical Mechanisms. <i>Diabetes</i> , 2010, 59, 1006-1015.	0.3	268
124	Common Genetic Variation in <i>GLP1R</i> and Insulin Secretion in Response to Exogenous GLP-1 in Nondiabetic Subjects. <i>Diabetes Care</i> , 2010, 33, 2074-2076.	4.3	106
125	Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results. <i>Journal of Diabetes Science and Technology</i> , 2010, 4, 1374-1381.	1.3	188
126	Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose. <i>Diabetes Research and Clinical Practice</i> , 2010, 90, 87-94.	1.1	19

#	ARTICLE	IF	CITATIONS
127	A model of GLP-1 action on insulin secretion in nondiabetic subjects. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 298, E1115-E1121.	1.8	36
128	Effects of Type 2 Diabetes on Insulin Secretion, Insulin Action, Glucose Effectiveness, and Postprandial Glucose Metabolism. <i>Diabetes Care</i> , 2009, 32, 866-872.	4.3	109
129	Physical Activity into the Meal Glucose-Insulin Model of Type 1 Diabetes: <i>In Silico</i> Studies. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 56-67.	1.3	95
130	Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 14-18.	4.3	58
131	Primary Defects in β -Cell Function Further Exacerbated by Worsening of Insulin Resistance Mark the Development of Impaired Glucose Tolerance in Obese Adolescents. <i>Diabetes Care</i> , 2009, 32, 456-461.	4.3	115
132	Run-to-Run Tuning of Model Predictive Control for Type 1 Diabetes Subjects: <i>In Silico</i> Trial. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1091-1098.	1.3	95
133	β -Cell Function and Insulin Sensitivity in Adolescents From an OGTT. <i>Obesity</i> , 2009, 17, 233-239.	1.5	16
134	Model predictive control of glucose concentration in type I diabetic patients: An <i>in silico</i> trial. <i>Biomedical Signal Processing and Control</i> , 2009, 4, 338-346.	3.5	162
135	<i>In Silico</i> Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 44-55.	1.3	621
136	Diabetes: Models, Signals, and Control. <i>IEEE Reviews in Biomedical Engineering</i> , 2009, 2, 54-96.	13.1	431
137	Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: Preliminary Studies in Padova and Montpellier. <i>Journal of Diabetes Science and Technology</i> , 2009, 3, 1014-1021.	1.3	127
138	Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on β -cell function in patients with type 2 diabetes: a model-based approach. <i>Diabetes, Obesity and Metabolism</i> , 2008, 10, 1212-1220.	2.2	74
139	Glucose Fluxes During OGTT in Adolescents Assessed by a Stable Isotope Triple Tracer Method. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2008, 21, 31-45.	0.4	17
140	Impaired fasting glucose with or without impaired glucose tolerance: progressive or parallel states of prediabetes?. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E428-E435.	1.8	34
141	Evaluating the Efficacy of Closed-Loop Glucose Regulation via Control-Variability Grid Analysis. <i>Journal of Diabetes Science and Technology</i> , 2008, 2, 630-635.	1.3	185
142	Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 459-464.	1.8	113
143	Use of labeled oral minimal model to measure hepatic insulin sensitivity. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008, 295, E1152-E1159.	1.8	19
144	Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content. <i>Diabetes</i> , 2008, 57, 2288-2295.	0.3	62

#	ARTICLE	IF	CITATIONS
145	Implications of Meal Library & Meal Detection to Glycemic Control of Type 1 Diabetes Mellitus through MPC Control. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2008, 41, 4228-4233.	0.4	11
146	GIM, Simulation Software of Meal Glucose-Insulin Model. Journal of Diabetes Science and Technology, 2007, 1, 323-330.	1.3	206
147	Two Years of Treatment With Dehydroepiandrosterone Does Not Improve Insulin Secretion, Insulin Action, or Postprandial Glucose Turnover in Elderly Men or Women. Diabetes, 2007, 56, 753-766.	0.3	60
148	Assessment of β -cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1-E15.	1.8	276
149	Effects of Nonglucose Nutrients on Insulin Secretion and Action in People With Pre-Diabetes. Diabetes, 2007, 56, 1113-1119.	0.3	39
150	Effect of 2 Years of Testosterone Replacement on Insulin Secretion, Insulin Action, Glucose Effectiveness, Hepatic Insulin Clearance, and Postprandial Glucose Turnover in Elderly Men. Diabetes Care, 2007, 30, 1972-1978.	4.3	85
151	Model Predictive Control of Type 1 Diabetes: An <i>in Silico</i> Trial. Journal of Diabetes Science and Technology, 2007, 1, 804-812.	1.3	265
152	Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β -cell function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2007, 9, 186-193.	2.2	136
153	Meal Simulation Model of the Glucose-Insulin System. IEEE Transactions on Biomedical Engineering, 2007, 54, 1740-1749.	2.5	745
154	DHEA in Elderly Women and DHEA or Testosterone in Elderly Men. New England Journal of Medicine, 2006, 355, 1647-1659.	13.9	527
155	Pathogenesis of Pre-Diabetes: Mechanisms of Fasting and Postprandial Hyperglycemia in People With Impaired Fasting Glucose and/or Impaired Glucose Tolerance. Diabetes, 2006, 55, 3536-3549.	0.3	182
156	A System Model of Oral Glucose Absorption: Validation on Gold Standard Data. IEEE Transactions on Biomedical Engineering, 2006, 53, 2472-2478.	2.5	228
157	A Model of Glucose Production During a Meal. , 2006, 2006, 5647-50.		14
158	Mixed Meal Simulation Model of Glucose-Insulin System. , 2006, 2006, 307-10.		32
159	Assessment of postprandial glucose metabolism: conventional dual- vs. triple-tracer method. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E800-E806.	1.8	46
160	Prediction of Postprandial Glycemic Exposure: Utility of fasting and 2-h glucose measurements alone and in combination with assessment of body composition, fitness, and strength. Diabetes Care, 2006, 29, 2708-2713.	4.3	5
161	Effects of Age and Sex on Postprandial Glucose Metabolism: Differences in Glucose Turnover, Insulin Secretion, Insulin Action, and Hepatic Insulin Extraction. Diabetes, 2006, 55, 2001-2014.	0.3	271
162	Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18273-18277.	3.3	354

#	ARTICLE	IF	CITATIONS
163	Mixed Meal Simulation Model of Glucose-Insulin System. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
164	Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E909-E914.	1.8	54
165	Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol: Minimal Model Assessment of β -Cell Responsivity and Insulin Sensitivity in Nondiabetic Individuals. Diabetes, 2005, 54, 3265-3273.	0.3	158
166	Acute inhibition of lipolysis does not affect postprandial suppression of endogenous glucose production. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E941-E947.	1.8	9
167	Insulin sensitivity by oral glucose minimal models: validation against clamp. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E954-E959.	1.8	101
168	Alterations in Postprandial Hepatic Glycogen Metabolism in Type 2 Diabetes. Diabetes, 2004, 53, 3048-3056.	0.3	267
169	Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E637-E643.	1.8	160
170	Mechanisms of the Age-Associated Deterioration in Glucose Tolerance: Contribution of Alterations in Insulin Secretion, Action, and Clearance. Diabetes, 2003, 52, 1738-1748.	0.3	373
171	The oral glucose minimal model: Estimation of insulin sensitivity from a meal test. IEEE Transactions on Biomedical Engineering, 2002, 49, 419-429.	2.5	188